Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth formulary coverage & prior auth | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 EmblemHealth Formulary (Large Group LG) — Drug Coverage and Utilization Management

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the plan formulary listing covered drugs, tiers, and utilization management rules for EmblemHealth large group plans; it informs members and providers which drugs are covered and any prior authorization, quantity limits, or step therapy requirements.

    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Formulary (Large Group LG) — Drug Coverage and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is annotated 'PA' and ensure dispensed quantities do not exceed listed quantity limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01Formulary effective/updated date
    LGFormulary ID
    PA, QL, ST, LA, SPUtilization flags used
    Tiers 1-2Tier levels shown
    877-793-6253Member services

    Formulary Coverage & Limits

    Oral peanut immunotherapy (Palforzia) — product-level constraints

    Coverage and limitations for Palforzia and allergen immunotherapy products:

    Palforzia product listings: PALFORZIA dosing levels 0 through 11 are listed with Requirements/Limits = LA, SP for each listed level (initial dose packs, levels 0–11, maintenance/titration packets).

    Indicates administrative constraints (Limited Access and Specialty Pharmacy) apply to all Palforzia dosing levels; providers must follow plan routing/dispensing requirements.

    Specialty drug administrative coverage flags

    Specialty oncology and targeted agents — coverage stance tied to listed Requirements/Limits flags

    PA/QL/LA/SP enforcement: Many specialty oncology and targeted agents are annotated with one or more administrative flags: PA (prior authorization), QL (quantity limits with specified amounts/timeframes), LA (limited access), and SP (specialty pharmacy). Coverage is contingent on meeting the listed Requirements/Limits for each product.see individual drug line items for exact QL values (e.g., 30 tablets/30 days; 240 capsules/30 days; therapy pack quantities)
    Policy Summary
    PayerEmblemHealth
    Policy2026 EmblemHealth Formulary (Large Group LG) — Drug Coverage and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is annotated 'PA' and ensure dispensed quantities do not exceed listed quantity limits.
    SourceLink
    On This Page
    Formulary Coverage & LimitsFormulary Line Items & Code TablesWhat Providers Must DoPolicy BackgroundAbbreviations & FlagsStep Therapy DesignationsSpecified Quantity Limits (QL)Specialty Pharmacy & Administration Sites

    Absence of required PA/QL/LA/SP documentation may result in denial; exact clinical medical-necessity criteria are not provided in these line items.

    General formulary coverage conditions

    Covered when plan-specific authorization and quantity limits are met for each listed drug

    General coverage conditions: A formulary-listed drug is covered when: the product appears on the plan formulary; any required Prior Authorization (PA) has been obtained; dispensed quantity does not exceed the listed Quantity Limit (QL); and the drug is routed through the Specialty Pharmacy (SP) channel when indicated.PA and QL as listed per drug (refer to each line item)

    Specific clinical indications/ICD-10 codes are not provided in these segments; follow EmblemHealth PA process for clinical justification.

    Formulary coverage with utilization management

    Coverage and utilization controls shown per drug entry

    Formulary coverage with controls: Each listed drug line includes a formulary tier and may include one or more administrative controls: PA (prior authorization), QL (quantity limit with specific amount and time window), LA (limited access), FF (fill/formulary flag), and SP (specialty pharmacy). Providers must follow the Requirements/Limits specified for the exact formulation and strength.Examples: MOUNJARO PA + QL (4 pens/28 days); OZEMPIC PA + QL (1 or 3 pens/28 days); GALAFOLD PA + QL (14 capsules/28 days).

    Provider should supply required documentation when submitting PA requests and ensure dispensing aligns with QL and SP routing.

    Operational coverage flags

    Coverage and utilization controls are applied as follows for individual drugs listed in these chunks

    PA+QL+SP flags: Drugs flagged with 'PA' require prior authorization before coverage; 'QL' denotes the maximum covered quantity in a specified time window; 'SP' indicates the product must be dispensed via the plan's specialty pharmacy program. Limited Access (LA) denotes restricted availability or additional routing requirements.See individual product entries for precise QL values and timeframes (examples include QL 8–14 tablets/301 days for MAVENCLAD; QL 540 mls/30 days for sodium oxybate; QL 4 syringes/28 days for CIMZIA).

    Failure to comply with these operational flags (missing PA, exceeded QL, or incorrect SP routing) may result in claim denial.

    Coverage of drugs listed in this formulary is plan-specific. Not all drugs in this list are paid for by all drug benefit plans; members and providers should check the member's Certificate of Coverage or contact member services for plan-specific coverage, cost-sharing, and limitations. The Certificate of Coverage and member portal are the authoritative sources for whether a listed product is covered for a particular member.

    The document excerpts provided do not include explicit clinical exclusion statements for products shown in these segments. Entries in these chunks are presented as drug line-items with associated administrative annotations (for example, ACA for Affordable Care Act preventive items) and do not define clinical exclusions.

    This segment lists drug products and their operational flags (e.g., PA, QL, LA, SP) but does not include explicit clinical exclusion language for individual drugs. Coverage constraints shown are administrative in nature and tied to line-item Requirements/Limits.

    The excerpt contains formulary entries and quantity limits for antidiabetic and related products but does not state explicit coverage exclusions. Where present, Requirements/Limits entries are administrative (e.g., QL) rather than clinical exclusion statements.

    In these chunks the listed information focuses on utilization controls and routing annotations (for example, PA, QL, LA, SP, and FF). There are no explicit clinical exclusion statements; the controls shown are administrative and may affect coverage if requirements are not met.

    No explicit Not Medically Necessary statements appear in the provided vaccine/toxoid excerpt; entries are vaccine listings annotated with administrative flags (for example, ACA) rather than clinical denial language.

    The oncology and specialty agent listings in these chunks include administrative flags (such as PA, QL, LA, SP) but do not contain explicit Not Medically Necessary declarations for specific drugs in the excerpt.

    The antidiabetic and hormone-related entries do not include any explicit Not Medically Necessary language in this excerpt; items are presented with drug tiers and, where applicable, quantity limits or other administrative annotations.

    Within these chunks (neurology and related therapeutic entries) there are no explicit Not Medically Necessary statements for listed products. The lines show Requirements/Limits such as QL or ST but do not state explicit medical necessity denials.

    Formulary Line Items & Code Tables

    Formulary Drug Listing (selected examples)mixed
    amoxicillin 125 mg chew tab, 250 mg chew tabAMOXICILLIN - amoxicillin (trihydrate) chew tab 125 mg, 250 mg
    amoxicillin cap 250 mg, 500 mgamoxicillin (trihydrate) cap 250 mg, 500 mg
    amoxicillin susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5mlamoxicillin (trihydrate) for susp
    amoxicillin tab 500 mg, 875 mgamoxicillin (trihydrate) tab
    amoxicillin & k clavulanate multiple strengths (susp, tabs, ER)amoxicillin & k clavulanate (including AUGMENTIN, ES-600, ER)
    ampicillin cap 500 mgampicillin cap 500 mg
    penicillin v potassium soln/tab 125 mg/5ml, 250 mg/5ml / tab 250 mg, 500 mgPENICILLIN V POTASSIUM
    cefaclor cap 250 mg, 500 mgCEFACLOR
    cefadroxil tab 1 gm; cap 500 mg; susp 250 mg/5ml, 500 mg/5mlCEFADROXIL
    cefdinir cap 300 mg; susp 125 mg/5ml, 250 mg/5mlcefdinir
    1–10 of 21
    1/3
    Sample listed oral antimicrobialsmixedCovered
    Dificid 200 mgfidaxomicin tab 200 mg (Dificid)
    NUZYRA 150 mgNUZYRA - omadacycline tosylate tab 150 mg (base equivalent)
    BAXDELA 450 mgBAXDELA - delafloxacin meglumine tab 450 mg (base equiv)
    CIPRO susp 250 mg/5ml, 500 mg/5mlciprofloxacin for oral suspension
    LEVOXIN tabslevofloxacin tab 250 mg, 500 mg, 750 mg
    Inhaled/antimycobacterial/aminoglycoside agentsmixedCovered
    ARIKAYCE 590 mgamikacin sulfate liposome inhalation suspension 590 mg/8.4ml
    TOBI PODHALER 28 mgtobramycin inhalation capsules 28 mg
    SIRTURO 20 mg/100 mgbedaquiline fumarate tab 20 mg (base equiv), 100 mg
    Antifungals and Hepatitis C direct-acting antiviralsmixedCovered
    NOXAFILposaconazole formulations (susp/DR)
    Vfendvoriconazole suspension/tab
    HARVONIledipasvir-sofosbuvir
    EPCLUSAsofosbuvir-velpatasvir
    MAVYRETglecaprevir-pibrentasvir
    SOFOSBUVIR (SOVALDI)sofosbuvir
    Antiretroviral combination productsmixedCovered
    BIKTARVYbictegravir-emtricitabine-tenofovir alafenamide
    GENVOYAelvitegravir-cobicistat-emtricitabine-tenofovir af
    TRIUMEQabacavir-dolutegravir-lamivudine
    Formulary line-items and flagsmixed
    SUNLENCA - lenacapavir sodium tab 300 mgDrug Tier = 2; Requirements/Limits = LA, QL (5 tablets/365 days), SP
    SUNLENCA - lenacapavir sodium tab 300 mgalternative listing: Requirements/Limits = LA, QL (4 tablets/365 days), SP
    SYMTUZA - darunavir-cobic-emtricitab-tenofov af tab 800-150-200-10 mgDrug Tier = 2; Requirements/Limits = QL (30 tablets/30 days)
    TIVICAY - dolutegravir sodium tab 50 mgDrug Tier = 2; Requirements/Limits = QL (60 tablets/30 days)
    TIVICAY PD - dolutegravir oral susp 5 mgDrug Tier = 2; Requirements/Limits = QL (360 tablets/30 days)
    TRIUMEQ - abacavir-dolutegravir-lamivudine tab 600-50-300 mgDrug Tier = 2; Requirements/Limits = QL (30 tablets/30 days)
    TYBOST - cobicistat tab 150 mgDrug Tier = 2; Requirements/Limits = QL (30 tablets/30 days)
    valacyclovir hcl tab 500 mg, 1 gm (Valtrex)Drug Tier = 1
    valganciclovir hcl for soln 50 mg/ml (Valcyte)Drug Tier = 1
    VEMLIDY - tenofovir alafenamide tab 25 mgDrug Tier = 2
    1–10 of 29
    1/3
    Vaccines/Toxoidsmixed
    VAXNEUVANCEpneumococcal 15-valent conjugate vaccine sus pref syr 0.5 ml
    VIVOTIFtyphoid vaccine cap delayed release
    YF-VAXyellow fever vaccine for subcutaneous suspension
    ADACELtetanus-diphtheria-acellular pertussis vaccine
    BOOSTRIXtetanus-diphtheria-acellular pertussis vaccine
    PEDIARIXdiphtheria-tetanus-acellular pertussis-hepatitis B-polio vaccine
    Passive immunizing agents / Palforzia stagesmixed
    BEYFORTUSnirsevimab-alip IM solution prefilled syringe 50 mg/0.5ml
    ENFLONSIAclesrovimab-cfor IM solution prefilled syringe 105 mg/0.7ml
    PALFORZIA LEVEL 0peanut powder initial 1 mg dose
    PALFORZIA LEVEL 11 (MAINT)peanut allergen powder maintenance packet 300 mg
    Antineoplastics / Targeted oncology agentsmixed
    abiraterone acetate 250 mgZytiga — tab 250 mg
    ALECENSAalectinib HCl cap 150 mg
    ALUNBRIGbrigatinib tablets (various strengths)
    BESREMIropeginterferon alfa-2b prefilled syringe 500 mcg/ml
    BOSULIFbosutinib cap/tab (various strengths)
    BRUKINSAzanubrutinib cap/tab
    CABOMETYXcabozantinib s-malate tabs
    CAPRELSAvandetanib tab
    COMETRIQcabozantinib s-malate cap kits
    COPIKTRAduvelisib cap
    1–10 of 15
    1/2
    Quantity limits examples and key formulary items
    Hydroxychloroquine sulfatetablet strengths listed: 100 mg, 300 mg, 400 mg (Drug Tier = 1)
    KRINTAFEL (tafenoquine succinate)tablet 150 mg listed (Drug Tier = 2)
    BENZNIDAZOLEtablets 12.5 mg and 100 mg listed with Requirements/Limits = LA
    Linezolid (Zyvox) oral suspensionsuspension 100 mg/5 ml listed; Requirements/Limits = PA
    Nitazoxanidetablet 500 mg listed; Requirements/Limits = QL (12 tablets/90 days)
    Nitrofurantoin formulationsMacrodantin and Macrobid formulations listed (Drug Tier = 1; some formulations may have PA or other flags)
    Vancomycin (oral)vancomycin HCl capsules and oral solution (Vancocin, Firvanq) listed (Drug Tier = 1)
    XIFAXAN (rifaximin)tablets 200 mg and 550 mg listed (Drug Tier = 2)
    CAYSTON (aztreonam lysine) inhalationfor inhalation solution 75 mg listed; Requirements/Limits = LA, SP
    Vaccines (selected examples)Multiple vaccines listed including ABRYSVO, AREXVY, COMIRNATY (2025–26), GARDASIL 9, SHINGRIX, SPIKEVAX and many seasonal/formulary vaccine entries (many flagged ACA)
    Mavenclad (cladribine)cladribine therapy packs (MAVENCLAD) listed with LA, PA, QL (various counts, e.g., 8–20 tablets per course), SP
    Mayzent (siponimod)siponimod fumarate tablets listed: 0.25 mg, 1 mg, 2 mg; Requirements/Limits include LA, PA, QL, SP
    Memantinememantine HCl oral solution 2 mg/ml and tablets 5 mg, 10 mg listed; Requirements/Limits include PA and QL examples
    Nicotine productsnicotine gum, lozenge, patch and starter kits listed and annotated ACA for smoking cessation coverage
    Tetrabenazine (Xenazine)tablets 12.5 mg and 25 mg listed; Requirements/Limits = PA, QL (examples shown), SP
    Opioid analgesics (examples)multiple opioid products listed including fentanyl patches, morphine sulfate formulations, hydrocodone combinations with associated PA/QL flags
    Formulary items and specific listed formulations (additional examples)
    Hydroxychloroquine sulfate (codes)Hydroxychloroquine sulfate tablets: 100 mg, 300 mg, 400 mg are explicitly listed in the formulary entries.
    KRINTAFEL — tafenoquine succinateTafenoquine succinate tablet 150 mg (KRINTAFEL) is listed as an antimalarial entry.
    BENZNIDAZOLE formulationsBenznidazole tablets 12.5 mg and 100 mg are listed with Requirements/Limits = LA.
    Linezolid oral suspension (Zyvox)Linezolid oral suspension 100 mg/5 ml is listed and annotated with Prior Authorization (PA).
    Nitazoxanide tabletNitazoxanide 500 mg tablet listed with Quantity Limit QL (12 tablets/90 days).
    Nitrofurantoin (Macrodantin, Macrobid)Nitrofurantoin macrocrystalline and monohydrate formulations (Macrodantin, Macrobid) are listed; some formulations may carry PA or other flags.
    Vancomycin oral products
    Quantity limits and listed product completeness (examples 28/60/120 etc.)
    Hydroxychloroquine sulfate — tablet strengths100 mg, 300 mg, 400 mg listed (Drug Tier = 1)
    KRINTAFEL — tafenoquine 150 mgTafenoquine succinate tablet 150 mg appears in the antimalarial entries.
    BENZNIDAZOLE — listed strengthsBenznidazole 12.5 mg and 100 mg tablets listed with Limited Access (LA)
    Linezolid (Zyvox) suspensionLinezolid oral suspension 100 mg/5 ml is present and requires Prior Authorization (PA)
    Nitazoxanide 500 mgNitazoxanide tablet 500 mg is listed with Quantity Limit QL (12 tablets/90 days)
    Nitrofurantoin (Macrodantin, Macrobid)Multiple nitrofurantoin formulations are listed (Macrodantin, Macrobid); some entries may carry PA or other flags.
    Vancomycin oral — capsule & solutionVancomycin HCl capsules and oral solution (Vancocin, Firvanq) listed (Drug Tier = 1)
    Pens/vials and specialty examples; formulation-specific entries
    Hydroxychloroquine sulfate entriesHydroxychloroquine sulfate tablets (100 mg, 300 mg, 400 mg) are included in the formulary listings.
    KRINTAFEL (tafenoquine) entryKRINTAFEL — tafenoquine succinate 150 mg tablet appears in the antimalarial section.
    BENZNIDAZOLE availabilityBenznidazole tablets 12.5 mg and 100 mg listed with Limited Access (LA) flag.
    Linezolid suspension (Zyvox)Linezolid oral suspension 100 mg/5 ml is listed and requires PA.
    Nitazoxanide QLNitazoxanide tablet 500 mg listed with QL = 12 tablets/90 days.
    Nitrofurantoin formulations includedNitrofurantoin products (Macrodantin, Macrobid) appear in the formulary; some formulations have utilization flags.
    Vancomycin oral formsVancomycin HCl capsules and oral solution (Vancocin, Firvanq) listed (Drug Tier = 1)
    Examples: 30 tablets/30 days; 540 mls/30 days; other QL/formulation examples
    Hydroxychloroquine sulfate — all tablet strengthsFormulary includes hydroxychloroquine sulfate tablets in 100 mg, 300 mg, and 400 mg strengths.
    KRINTAFEL (tafenoquine) 150 mgTafenoquine succinate tablet 150 mg (KRINTAFEL) is listed in antimalarial group.
    BENZNIDAZOLE — listed tabletsBenznidazole tablet strengths 12.5 mg and 100 mg included; annotated Limited Access (LA).
    Linezolid oral suspension 100 mg/5 mlLinezolid (Zyvox) oral suspension 100 mg/5 ml is listed and requires Prior Authorization (PA).
    Nitazoxanide tablet 500 mgNitazoxanide 500 mg tablet listed with QL (12 tablets/90 days).
    Nitrofurantoin formulations (Macrodantin, Macrobid)Nitrofurantoin macrocrystalline and monohydrate formulations are present; utilization flags may apply to certain presentations.
    Vancomycin HCl capsule and oral solution

    What Providers Must Do

    Prior Authorization

    Obtain Prior Authorization for PA‑marked drugs

    Obtain prior authorization before prescribing or dispensing any drug annotated with 'PA' on the formulary; failure to obtain PA may result in the plan not covering the drug.

    • Applies to all products with Requirements/Limits = PA.
    • Follow EmblemHealth's PA submission process and include required clinical justification.
    Prior Authorization

    Prior Authorization for select specialty agents

    Submit PA for high‑cost specialty antiviral and antifungal agents that list 'PA' (e.g., posaconazole formulations, ledipasvir‑sofosbuvir) prior to claim adjudication.

    • Examples: NOXAFIL (posaconazole) lists Requirements/Limits = PA.
    • HARVONI (ledipasvir‑sofosbuvir) lists Requirements/Limits = PA, QL, SP.
    Prior Authorization

    Submit authorization requests for PA‑marked products

    Do not dispense drugs marked 'PA' without prior authorization; submit an authorization request with supporting clinical documentation when required.

    • Many line items are explicitly marked 'PA' in the Requirements/Limits column.
    • Providers/pharmacies must supply documentation to support PA requests.
    Prior Authorization

    PA for specialty oncology agents (PA + SP)

    Prior authorization is required for specialty oncology/targeted oral agents annotated with 'PA' and often 'SP' — obtain PA and ensure specialty pharmacy routing when indicated.

    • Examples include abiraterone (PA, QL, SP) and multiple agents in chunks 61–73 with LA/PA/QL/SP flags.
    • Specialty oncology oral agents often require SP dispensing in addition to PA.
    Prior Authorization

    Obtain PA for many listed drugs

    For many listed specialty and oral oncology drugs, obtain PA before coverage; check each line item's Requirements/Limits for PA and QL details.

    • Line items show PA and specific QL windows (e.g., 28 tablets/28 days).
    • Coverage is contingent on PA being completed where indicated.
    Prior Authorization

    Obtain PA and respect Quantity Limits

    When a product shows 'PA' and a QL, obtain prior authorization and ensure dispensed quantity does not exceed the listed quantity limit.

    • Examples: HARVONI PA with QL (28 tablets/28 days).
    • Claims exceeding QL or missing PA may be denied.
    Prior Authorization

    MOUNJARO: PA required; observe pen‑count QL

    MOUNJARO requires prior authorization and is subject to a quantity limit (QL) — either 4 pens/180 days or 4 pens/28 days depending on strength; obtain PA and authorize the correct QL.

    • MOUNJARO (tirzepatide) Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days).
    • Include supporting clinical justification with the PA request.
    Prior Authorization

    GLP‑1/DPP‑4 agents: PA and QL enforcement

    GLP‑1 and DPP‑4 agents (e.g., OZEMPIC, TRULICITY, RYBELSUS) list PA and/or QL — obtain prior authorization and follow the product‑specific quantity limits.

    • OZEMPIC Requirements/Limits = PA, QL (1 pen/28 days or 3 pens/28 days).
    • RYBELSUS and TRULICITY similarly list PA/QL requirements in the formulary.
    Prior Authorization

    PA and specialty pharmacy routing for endocrine agents

    Specialty endocrine agents (e.g., GALAFOLD, FOLLISTIM AQ, ACTHAR) require prior authorization and are often designated SP; obtain PA and process through specialty pharmacy when required.

    • GALAFOLD Requirements/Limits = LA, PA, QL (14 capsules/28 days), SP.
    • FOLLISTIM AQ lists PA, QL (varies), SP; ACTHAR lists LA, PA, SP.
    Prior Authorization

    PA required for listed specialty and LA drugs

    Obtain prior authorization for specified specialty and limited‑access drugs listed (e.g., GENOTROPIN, FOLLISTIM AQ) before dispensing; follow PA and SP routing noted per line item.

    • GENOTROPIN Requirements/Limits = PA, SP.
    • FOLLISTIM AQ cartridges require PA and QL and are SP handled.
    Prior Authorization

    PA may apply to select non‑specialty products

    Some non‑specialty products (e.g., nimodipine oral solutions) may also require PA; check the Requirements/Limits column and submit PA when PA is listed.

    • NYMALIZE/NIMODIPINE entries show QL and PA in the Requirements/Limits field.
    • Even conventional therapies may carry PA requirements.
    Prior Authorization

    Obtain PA whenever indicated on line item

    When the Requirements/Limits field indicates PA, the provider must obtain prior authorization before the drug is covered; this applies across therapeutic classes where PA is shown.

    • Many entries specify PA alongside QL, LA or SP; provider must obtain PA when PA is listed.
    • Coverage depends on completion of payer PA procedures.
    Prior Authorization

    PA required for listed PA drugs — verify per line item

    Prior authorization is required for the PA‑annotated products listed throughout the formulary; check each product's Requirements/Limits for exact PA status and quantity limits.

    • Entries marked 'PA' require authorization; some also indicate LA, QL, or SP.
    • Providers should review the specific product line for PA and QL details before prescribing.
    Prior Authorization

    PA for select specialty agents (Esbriet, CF modulators, biologics)

    Select specialty agents (e.g., Esbriet, CF modulators, biologics) require prior authorization; submit PA and adhere to any QL/SP directions shown for those products.

    • Esbriet (pirfenidone 801 mg) Requirements/Limits = PA, QL (90 tablets/30 days), SP.
    • CF modulators TRIKAFTA/SYMDEKO list LA, PA, QL and SP handling.
    Prior Authorization

    PA for select specialty/orphan drugs (PROCYSBI, FILSPARI, VANRAFIA)

    Certain branded specialty/orphan drugs (e.g., PROCYSBI, FILSPARI, VANRAFIA) require prior authorization and may be limited‑access and specialty‑dispensed; obtain PA and route to specialty pharmacy.

    • PROCYSBI Requirements/Limits = LA, PA, SP.
    • FILSPARI Requirements/Limits = LA, PA, QL (30 tablets/30 days), SP.
    Prior Authorization

    PA required for numerous specialty agents (e.g., MAVENCLAD)

    Many specialty agents (e.g., MAVENCLAD, MAYZENT, LUMRYZ) are annotated with PA and QL and require prior authorization and specialty pharmacy processing; obtain PA and confirm QL before dispensing.

    • MAVENCLAD Requirements/Limits = LA, PA, QL (8–14 tablets/301 days), SP.
    • LUMRYZ Requirements/Limits = LA, PA, QL; specialty handling indicated.
    Prior Authorization

    Obtain PA where annotated

    Obtain prior authorization for products annotated 'PA' wherever the Requirements/Limits column indicates it — verify each product line before prescribing or dispensing.

    • PA is required where annotated 'PA' in the Requirements/Limits column.
    • Check the formulary line item for precise PA/Q L/SP flags.
    Step Therapy

    Follow Step Therapy (ST) requirements where indicated

    Step therapy (ST) requires trial of preferred first‑line drugs before the plan will cover higher‑tier or alternative agents; follow ST rules where 'ST' is indicated and submit exceptions if clinically appropriate.

    • ST means the member must try specified drugs first; examples: FETZIMA, FLUOXETINE DR, FANAPT show ST.
    • Exceptions to ST may be requested per payer processes.
    Step Therapy

    Step therapy sequences not specified in extract — verify per item

    No explicit step therapy sequences are listed in this extract for most products; check individual formulary entries for 'ST' annotations before applying step edits.

    • Most entries show PA/QL/LA/SP but not detailed step sequences.
    • Verify product‑level details where ST may apply.
    Documentation Required

    Follow payer authorization processes and contact member services as needed

    When a PA/QL/LA/SP/ST requirement applies, follow the plan's authorization processes, provide necessary clinical documentation, and contact Member Services for benefit questions.

    • Member Services phone is listed in the plan materials (see member ID card or portal).
    • Follow PA submission instructions and include clinical justification as requested.
    Note

    Palforzia: confirm enrollment/site and specialty dispensing for levels

    Palforzia dosing levels are annotated with LA and SP — providers should confirm required enrollment and site‑of‑care or dispensing constraints (e.g., specialty pharmacy or clinic administration) before initiating therapy.

    • PALFORZIA LEVELS 0–11 list Requirements/Limits = LA, SP.
    • Levels include initial/starter, titration, and maintenance packets with LA/SP flags.
    Step Therapy

    Step therapy not listed here — verify full policy for ST rules

    Step therapy details are not listed for most products in this extract; where step therapy is not shown, rely on PA/QL/LA/SP flags and check full policy or contact the plan for ST requirements.

    • Many products use PA/QL/LA/SP flags rather than explicit step sequences.
    • For agents marked 'ST' consult the formulary line item for specifics (e.g., KERENDIA).
    Note

    Verify ACA and LA flags for contraceptives

    Contraceptives designated ACA/LA may have special coverage considerations; verify ACA status for no‑cost coverage and LA for limited availability before prescribing.

    • Examples: ANNOVERA and other contraceptives list Requirements/Limits = ACA, some also show LA or FF.
    • ACA flag may indicate preventive coverage under applicable rules.
    Documentation Required

    Review flags and provide required supporting documentation

    Providers should review the formulary entries for step therapy, PA, QL, LA, and SP annotations and supply documentation accordingly when requesting coverage or prior authorization.

    • The Requirements/Limits column lists flags (PA, QL, LA, SP, ACA, FF) adjacent to drug entries.
    • Submit clinical justification and any required forms with PA requests.
    Step Therapy

    Apply step therapy for agents annotated 'ST' (KERENDIA example)

    KERENDIA and some other agents explicitly list 'ST' — ensure member has met step therapy requirements before requesting coverage or include rationale in a PA if requesting an exception.

    • KERENDIA Requirements/Limits = QL (30 tablets/30 days), ST.
    • If ST not met, submit exception rationale with PA.
    Note

    Act on utilization management flags shown per product

    Observe utilization management flags (ACA, LA, PA, QL, SP) shown in the Requirements/Limits column and act accordingly when submitting PA requests or routing prescriptions.

    • Some agents carry ACA designations indicating preventive coverage; others carry LA/SP that limit site or channel.
    • Check each product line for the specific flag set.
    Step Therapy

    No ST details in this segment — use PA/QL guidance or contact plan

    Step therapy sequences are not explicitly detailed in many segments of this formulary; where ST is not annotated, rely on PA/QL rules and contact the plan for clarification if needed.

    • The formulary primarily uses PA/QL/LA/SP flags rather than step algorithms in these chunks.
    • Contact EmblemHealth for complete ST policy when required.
    Documentation Required

    Confirm Limited‑Access (LA) requirements and document in PA

    Limited‑access (LA) indicators denote restricted dispensing or additional criteria; confirm LA requirements and include necessary documentation in PA requests when LA is shown.

    • Examples: GATTEX and LIVMARLI show LA flags in Requirements/Limits.
    • LA often accompanies PA and SP, requiring extra steps for coverage.
    Step Therapy

    Verify step therapy trials for ST‑marked agents

    For agents annotated with ST (e.g., AUVELITY, FETZIMA, TRINTELLIX), confirm prior trial of first‑line therapies per step therapy or include justification in a PA to request coverage.

    • FETZIMA Requirements/Limits = QL (30 capsules/30 days), ST.
    • AUVELITY and others listed with ST require step edits prior to coverage.
    Step Therapy

    Apply ST for gabapentin/HORIZANT where annotated

    Some gabapentin formulations and HORIZANT are marked with 'ST' — ensure step therapy requirements are met for these products before coverage is requested.

    • Gralise (gabapentin once‑daily) entries show QL and ST flags.
    • If ST not met, include clinical rationale when requesting PA.
    Step Therapy

    Step therapy applies where annotated (Imitrex StatDose example)

    When a product is annotated with 'ST' (e.g., Imitrex StatDose), follow the step therapy requirement before coverage or document clinical reasons for exception in the PA submission.

    • Imitrex StatDose system annotated with Requirements/Limits = QL (12 doses/30 days), ST.
    • Submit exception rationale if member has not completed required steps.
    Documentation Required

    Contact Member Services and verify member benefits before prescribing

    Contact Member Services for benefit questions and member eligibility; verify coverage, PA process, and any site‑of‑care or specialty pharmacy routing before initiating therapy.

    • Member should check Certificate of Coverage or call the number on their ID card.
    • Providers can use member portal my.emblemhealth.com for plan details.
    Documentation Required

    Provide required clinical documentation with PA/QL submissions

    Include supporting clinical documentation with PA/QL requests — demonstrate medical necessity, prior therapies tried, and intended dose/quantity so the PA can be processed timely.

    • Prescribers/pharmacies must supply documentation supporting PA where 'PA' is indicated.
    • Supply records showing prior therapy trial when ST or PA criteria apply.
    Documentation Required

    Reference formulary flags and include item‑specific documentation in PA

    Documentation should reference the Requirements/Limits flags on the formulary line (PA, QL, LA, SP) and include details needed to meet the plan's authorization criteria.

    • The formulary displays PA/QL/LA/SP flags adjacent to drug entries.
    • Ensure PA requests reference the exact product and its listed limits.
    Billing Rule

    Document and adhere to specified Quantity Limits

    When quantity limits are specified (e.g., tablets/30 days or pens/28 days), document intended dispense quantities to match the listed QL and include that in the PA or claim.

    • Abiraterone lists QL 120 tablets/30 days or 60 tablets/30 days depending on strength.
    • Ensure dispense quantity on the claim does not exceed the listed QL.
    Billing Rule

    Route SP products through specialty pharmacy and include PA documentation

    Route prescriptions through the designated specialty pharmacy channel when a product is marked 'SP'; specialty routing and PA documentation are required for SP agents.

    • Products marked SP must be dispensed through specialty pharmacy per formulary.
    • Examples include many specialty endocrine and biologic agents.
    Documentation Required

    Include diagnosis and treatment details with PA/QL requests

    Include required documentation for PA and QL on authorization requests — provide diagnosis, prior treatments, dose, and requested quantity per the formulary line item.

    • Prescriptions with 'PA' must include clinical justification per payer PA process.
    • PA requests should reference the product's QL (e.g., 4 syringes/28 days) when applicable.
    Documentation Required

    Obtain PA and ensure specialty pharmacy handling for SP agents

    Specialty products often require both PA and specialty pharmacy handling (e.g., ACTHAR, CARBAGLU, SENSIPAR); obtain PA and ensure SP enrollment or routing as listed.

    • ACTHAR Requirements/Limits = LA, PA, SP.
    • CARBAGLU and SENSIPAR list PA and SP requirements.
    Documentation Required

    Address PA/LA/QL/SP flags in authorization documentation

    When a drug is flagged with any of PA/LA/QL/SP, include documentation addressing those specific requirements in the PA submission to expedite processing.

    • Providers must supply documentation to satisfy PA, LA, QL, or SP requirements as requested by the plan.
    • Reference the formulary line item's flags in the PA submission.
    Billing Rule

    Document formulation and adhere to formulation‑specific QL

    For products with formulation‑specific QL (e.g., liquids, oral solutions, starter kits), document the requested formulation and match the dispense quantity to the listed QL on the claim or PA.

    • Examples: QBRELIS lisinopril oral solution QL 1200 mls/30 days; esomeprazole suspension packets QL 60 packets/30 days.
    • Document bottle/pack size and days' supply to align with QL.
    Documentation Required

    Supply medical necessity and SP routing details for PA/SP products

    For drugs requiring PA and SP, supply medical necessity documentation and evidence of specialty pharmacy routing where requested to support approval.

    • Prescribers must supply documentation supporting medical necessity when requesting PA for 'PA' and 'SP' drugs.
    • Examples include NUCALA and GALAFOLD which list LA/PA/QL and SP handling.
    Billing Rule

    Dispense only within listed Quantity Limits

    Confirm and adhere to the quantity limits specified for each product; dispensing beyond the listed QL may cause claim denial or require additional justification.

    • Quantity limits are specified for many products (e.g., ELIMIRON QL 90 capsules/30 days).
    • Exceeding QL may trigger denial or require justification (e.g., JYNARQUE therapy pack QL 56/28 days).
    Billing Rule

    Adhere to specified QL on claims and PAs

    Adhere to the specified quantity limit listed for each product on the formulary; ensure claim submission reflects the allowed amount and timeframe.

    • Prescribers must submit PA where 'PA' is listed and adhere to QL and SP routing shown for each product.
    • Examples: ELIMIRON QL 90 capsules/30 days; various specialty products list QL and SP.
    Denial Risk

    Obtain PA and respect QL to avoid noncoverage

    Obtain prior authorization when required and ensure dispensed quantities do not exceed the formulary's QL; failure to obtain PA or exceed QL may result in noncoverage or denial.

    • Failure to obtain required PA may result in the plan not covering the drug.
    • Claims exceeding QL or missing PA/SP/LA routing may be denied.
    Denial Risk

    Risk of denial if PA/QL/ST/LA/SP not followed

    Failure to obtain required prior authorization or to comply with utilization management flags (PA, QL, ST, LA, SP) may result in the plan denying coverage for the drug.

    • Utilization management restrictions are applied as indicated next to drug names.
    • Denial risk increases when PA is not obtained or QL/ST requirements are unmet.
    Denial Risk

    Denial risk for exceeding QL or missing PA/SP/LA

    Claims that exceed quantity limits, lack required PA, or are not routed through required site/program channels (SP/LA) may be denied; verify limits and obtain PA prior to dispensing.

    • Requests exceeding QL or lacking PA/SP/LA may be denied per formulary rules.
    • Ensure prescriptions are processed through the designated specialty pharmacy when SP is listed.
    Denial Risk

    Products with PA/QL/LA/SP flags may trigger denials if unmet

    Products flagged with PA, QL, LA, or SP may trigger denial if the corresponding requirements are not met during claim or authorization processing; verify and document compliance.

    • PA, QL, LA, SP flags commonly accompany specialty agents and oncology products.
    • Claims for these products should include documentation of PA and appropriate dispensing channel.
    Prior Authorization

    PA/SP/LA/QL flags trigger authorization requirements for specialty agents

    Authorization requirements for specialty agents are triggered by flags such as 'PA', 'QL', 'LA', or 'SP' — obtain PA and route through specialty pharmacy when shown to avoid denial.

    • Many specialty agents list PA and SP; lack of PA or SP enrollment may trigger coverage denial.
    • Examples include GALAFOLD, FOLLISTIM AQ, and other specialty endocrine agents.
    Denial Risk

    Confirm PA/QL/SP to avoid denials for listed drugs

    Requests for listed drugs without PA, exceeding QL, or not routed to specialty pharmacy (SP) may be denied per plan requirements; confirm and document authorization prior to dispensing.

    • The formulary states coverage contingent on PA completion and adherence to QL and SP where indicated.
    • Providers should confirm authorization prior to dispensing specialty or restricted products.
    Prior Authorization

    PA required for GLP‑1/related agents — obtain PA to prevent denial

    Drugs listed with PA, LA+PA, or PA+QL (e.g., MOUNJARO, OZEMPIC, TRULICITY) require prior authorization and may be denied if PA is not obtained.

    • MOUNJARO Requirements/Limits = PA, QL (pen counts per timeframe).
    • OZEMPIC and TRULICITY list PA and QL in the formulary entries.
    Denial Risk

    PA and Specialty Pharmacy enrollment required for SP products

    Specialty products that require both PA and SP enrollment may be denied if either requirement is not met; ensure PA approval and specialty pharmacy routing before dispensing.

    • Lack of required PA or SP enrollment may trigger coverage denial for listed specialty products.
    • Examples include GENOTROPIN and ACTHAR which list PA and SP.
    Denial Risk

    Exceeding Quantity Limits may trigger denial

    Exceeding a product's specified Quantity Limit (e.g., JYNARQUE therapy pack QL 56 tablets/28 days) may trigger denial or require additional justification; verify QL before dispensing.

    • JYNARQUE therapy pack Requirements/Limits = QL (56 tablets/28 days).
    • Exceeding QL may prompt denial or request for justification.
    Denial Risk

    Noncompliance with PA/QL/SP may lead to claim denial

    Claims for drugs marked with PA, QL, or SP that do not meet the listed authorization criteria may be denied — obtain PA and ensure dispense quantities and routing conform to the line item.

    • Many products (e.g., MAVENCLAD, ADALIMUMAB biosimilars) list PA and QL and require SP handling.
    • Verify and document that PA is approved and that the specialty pharmacy is used when required.
    Denial Risk

    Denial risk for missing PA/ST or other utilization flags

    Failure to obtain PA, to follow ST where indicated, or to comply with QL/SP/LA flags can result in claim denial; confirm authorization status before initiating specialty or restricted therapies.

    • Claims for drugs listed with PA or ST may be denied without prior approval.
    • Confirm PA and enrollment in required programs for LA/SP drugs.
    Denial Risk

    PA and QL enforcement may result in denials if unmet

    Prior authorization and quantity‑limit requirements are enforced; claims for drugs listed with PA or exceeding QL may be denied if authorization is not obtained or limits exceeded.

    • The formulary repeatedly notes PA and QL enforcement across many line items.
    • Obtain PA and ensure dispense quantities match QL to avoid denial.
    Note
    Note
    Note
    Note
    Note

    Policy Background

    This formulary is organized by therapeutic class and lists available strengths, formulations, tiers, and utilization management designations. Each line-item may include one or more requirement flags such as PA (Prior Authorization), QL (Quantity Limit, shown as a defined amount per time period), LA (Limited Access), SP (Specialty Pharmacy), or ACA (Affordable Care Act–mandated items). Coverage for a listed drug is contingent on meeting the plan-specific administrative requirements shown for that product (for example, obtaining required PA, not exceeding the listed QL, and using the specialty channel where SP is indicated).

    Abbreviations & Flags

    inv-96: PA — Prior Authorization
    PA — Prior AuthorizationPA denotes Prior Authorization: the plan requires you or your doctor to get approval before filling the prescription; coverage may be denied without approval
    QL — Quantity LimitQL denotes Quantity Limit: the plan limits the amount of the drug it will cover (expressed with a quantity and time window)
    ST — Step TherapyST denotes Step Therapy: the plan may require trying specified first‑line drugs before covering alternatives
    LA — Limited AvailabilityLA denotes Limited Availability: the drug may only be available at certain pharmacies or channels
    SP — Specialty DrugSP denotes Specialty Drugs: products that may require special handling, monitoring, or specialty pharmacy distribution
    inv-97: QL — Quantity Limit
    QL — Quantity Limit (definition)QL: Quantity Limit — for certain drugs the plan limits the amount it will cover within a specified time window (e.g., tablets/30 days)
    Examples of time windowsCommon QL windows shown in the document include per 28 days, per 30 days, per 90 days, per 180 days, and per 365 days
    Impact on dispensingDispensing must adhere to the listed QL on claims and PA requests; exceeding QL may trigger denial or request for justification
    inv-98: ST — Step Therapy
    ST — Step Therapy (definition)ST denotes Step Therapy: member must first try specified preferred drugs before the plan will cover alternative therapies; exceptions can be requested
    Operational noteStep therapy requirements are applied when 'ST' is annotated next to a product and are enforced through the plan's PA/processes
    Not always listedThe extract notes that explicit ST sequences are not present for many products; PA/QL/LA/SP are the primary controls in this segment
    inv-99: LA — Limited Availability
    LA — Limited Availability (definition)LA denotes Limited Availability: the medication may be restricted to certain pharmacies, channels, or require specific handling/site-of-care
    Operational effectLA flags often accompany PA/QL/SP and indicate restricted distribution or site-of-care requirements
    Examples in documentMany specialty agents and therapy packs are annotated LA alongside PA and QL (see oncology and specialty listings)
    inv-100: SP — Specialty Drug
    SP — Specialty Drug (definition)SP denotes Specialty Drug: typically requires specialty pharmacy handling, may need special monitoring or administration processes
    Routing requirementProducts marked SP must generally be dispensed through the plan's specialty pharmacy channel and may require PA
    Common pairingSP is frequently listed with PA and QL for high-cost biologics, oncology, and orphan drugs
    inv-101: Requirement/Limit flags general
    Common requirement/limit flagsFlags used in the Requirements/Limits column include: PA (Prior Authorization), QL (Quantity Limit), LA (Limited Availability), SP (Specialty Pharmacy), ACA (Affordable Care Act), FF (Frozen Formulary)
    Where shownThese abbreviations appear adjacent to individual drug line items and govern coverage/processing
    EnforcementFailure to meet listed flags (e.g., no PA, exceed QL, not routed to SP) may lead to denial of coverage
    inv-102: Requirements/Limits flags (detailed abbreviations)
    PAPrior Authorization — administrative approval required before the drug is covered; listed as 'PA' next to products
    QLQuantity Limit — maximum covered quantity in a specified time window (e.g., 30 tablets/30 days)
    LALimited Availability — product may be available only at certain pharmacies or through specific channels
    SPSpecialty Pharmacy — product must be dispensed through specialty pharmacy; often paired with PA and QL
    inv-103: PA (definition example)
    PA example (antivirals)HARVONI / SOVALDI — annotated with PA and QL (28 tablets/28 days) and SP where indicated
    PA example (antiretrovirals)ISENTRESS chewable — QL 180 tablets/30 days; some antiretrovirals also carry PA annotations
    Operational implicationWhen PA is shown, providers must submit authorization requests per EmblemHealth procedures prior to dispensing
    inv-104: QL (definition example)
    QL example (GLP‑1/antidiabetics)JANUVIA / JARDIANCE / FARXIGA etc. — common QL shown as 30 tablets/30 days; pens examples shown as 4 pens/28 days or 4 pens/180 days
    Insulin QL examplesInsulin presentations list QL such as 33 pens/30 days, 10 vials/30 days, or 100 mls/30 days depending on presentation
    Formulation-specific limitsQLs vary by formulation (tablets, pens, cartridges, mls) and must be observed on claims/PA
    inv-105: SP (definition example)
    Specialty routing (SP) exampleTYVASO / TREPOSTINIL / UPTRAVI — products marked SP and LA often require specialty pharmacy or infusion/authorized sites
    Impact on distributionSP designation indicates dispensing via specialty pharmacy; LA may further restrict site of care
    DocumentationSpecialty products typically require PA and supporting documentation when requesting coverage
    inv-106: PA (definition repeated)
    PA — Prior Authorization (restate)Prior Authorization (PA) requires approval before the plan will cover the drug; lack of PA may result in denial
    When appliedPA appears adjacent to many specialty and high‑cost agents across the formulary
    Provider actionSubmit required clinical justification and documentation per payer PA process
    inv-107: QL (definition repeated)
    QL — common monthly limitsQuantity Limits define maximum covered supply per time window (e.g., 30 tablets/30 days; 4 pens/28 days) and are enforced at claim/PA
    Examples across drug classesQLs apply to antidiabetics, insulins, biologics, and many oral specialty agents; units differ by formulation
    Consequence of exceedanceExceeding a QL can trigger denial or a request for justification/documentation
    inv-108: SP (definition repeated)
    SP — Specialty Pharmacy (restate)Specialty Pharmacy designation (SP) indicates that the medication must be dispensed through specialty pharmacy channels
    Associated controlsSP is commonly paired with PA and QL and may require specialty enrollment and documentation
    Site-of-care noteSome SP/LA products may also be limited to infusion centers or authorized sites
    inv-109: LA (definition repeated)
    LA — Limited Access (restate)LA indicates limited availability or restricted access; may require administration at specific sites or specialty channels
    Common pairingLA commonly appears with PA and QL for oncology and orphan products
    Operational impactProviders must follow any site-of-care or dispensing restrictions noted when LA is flagged
    inv-110: PA (definition repeated)
    PA — Prior Authorization (restate)Prior Authorization (PA) — coverage requires approval before dispensing for products annotated 'PA'
    Common scopePA is applied across specialty, oncology, and other high‑cost agents throughout the formulary
    ActionObtain PA per EmblemHealth procedures before dispensing to avoid denial
    inv-111: QL (definition repeated)
    QL — Quantity Limit (restate)Quantity Limit — specifies maximum covered quantity in the stated time window (e.g., 4 pens/28 days; 33 pens/30 days)
    ExamplesInsulin and pen/cartridge presentations commonly show QLs per 28 or 30 days
    ProcessingClaims and PA requests must reflect QL units/period to be processed correctly
    inv-112: LA (definition repeated)
    LA — Limited Access (restate)Limited Access restricts dispensing to certain channels or settings and is frequently paired with PA and SP
    ExamplesMany specialty agents list LA with PA and QL (e.g., TYVASO, TREPOSTINIL) indicating restricted distribution
    Provider implicationFollow site-of-care and specialty routing when LA is present to ensure coverage
    inv-113: SP (definition repeated)
    SP — Specialty (restate)Specialty designation indicates the drug is managed via specialty pharmacy and often requires PA and QL
    DocumentationSpecialty drugs typically require documentation of medical necessity and specialty routing on PA requests
    Potential denialsFailure to enroll or route through SP can result in claim denial
    inv-114: PA (definition repeated)
    PA — Prior Authorization (restate)Prior Authorization: administrative approval required before coverage; absence may lead to denial
    Where annotatedPA annotations appear throughout the formulary adjacent to many specialty and high‑cost agents
    Provider actionSubmit PA with required clinical documentation as requested by the plan
    inv-115: QL (definition repeated)
    QL — Quantity Limit (restate)Quantity Limit — maximum amount covered in the listed time window (examples shown across the formulary)
    Examples of windowsCommon windows include 28 days, 30 days, 84 days, 180 days, 301 days, and 365 days depending on product
    Claims complianceDispensed quantities must match QL on claims/PA to avoid denial or adjustment
    inv-116: SP (definition repeated)
    SP — Specialty product (restate)SP: specialty products are managed through specialty pharmacy channels and often require PA and QL controls
    ExamplesMany orphan and biologic therapies list SP with LA and PA (see MAVENCLAD, LUMRYZ, TYVASO)
    Routing requirementProviders should route prescriptions to the specialty pharmacy as noted for SP items
    inv-117: LA (definition repeated)
    LA — Limited Access (restate)LA — indicates restricted availability or access; may require specific dispensing arrangements or site-of-care
    ACA — Affordable Care Act flagACA appears next to many preventive or smoking‑cessation products indicating ACA coverage requirements
    Practical noteCheck the line item flags (LA/PA/QL/SP/ACA) to determine required provider actions and coverage pathways
    inv-118: PA (definition repeated)
    PA — Prior Authorization (restate)PA — approval required before dispensing; annotated near drugs that need administrative review
    Enforcement riskClaims without required PA may be denied; follow EmblemHealth PA process
    Common pairingsPA commonly appears with QL and SP on specialty agents
    inv-119: QL (definition repeated)
    QL — Quantity Limit (restate)QL — maximum amount covered per listed time window; used across multiple therapeutic classes
    Examples from the formularyExamples include 30 tablets/30 days, 56 packets/28 days, 112 capsules/28 days, and larger multi‑month packs
    Provider implicationAdhere to product‑specific QLs when submitting PAs or claims to avoid denial
    inv-120: SP (definition repeated)
    SP — Specialty (restate)SP — specialty drugs requiring specialty pharmacy distribution and additional controls (PA/QL/LA)
    ExamplesMany biologics and orphan drugs list SP with PA and QL (e.g., biosimilars, adalimumab family, enzyme therapies)
    ActionEnsure specialty routing/enrollment when SP is annotated to secure coverage
    inv-121: ACA — ACA coverage requirement
    ACA — Affordable Care Act flagACA indicates a coverage requirement tied to ACA preventive or smoking‑cessation benefits and may affect cost‑sharing/coverage
    ExamplesVaccines and nicotine replacement therapies in the formulary are often flagged ACA
    ImplicationACA‑flagged products may be covered differently per plan and member eligibility
    inv-122: SP (definition repeated)
    SP — Specialty (repeat)Specialty designation indicates management through specialty pharmacy channels and often requires PA/QL
    Common co‑flagsSP is frequently annotated with LA and PA for complex therapies
    Provider instructionPrescriptions for SP products should follow specialty pharmacy routing as noted
    inv-123: QL (definition repeated)
    QL — Quantity Limit (repeat)Quantity Limit — maximum covered quantity in the specified time window (e.g., '4 syringes/28 days')
    Units vary by formulationQL units may be tablets, capsules, pens, syringes, cartridges, mls, vials, kits, or boxes depending on product
    Claims noteEnsure claims reflect the QL units and period to avoid denial
    inv-124: LA (definition repeated)
    LA — Limited Access (repeat)Limited Access indicates additional utilization controls restricting dispensing to specified channels or criteria
    ExamplesLA appears with PA and SP for many specialty and orphan drugs in the formulary
    Provider actionFollow LA‑specific routing/requirements when present to ensure coverage

    Step Therapy Designations

    Coverage noteImplication
    Step therapy (ST) designation indicates the plan requires trial of specified preferred drugs before covering alternatives.Providers must follow ST requirements where annotated on formulary line items; exceptions may be requested per plan process.
    Abbreviations: ST = Step Therapy; PA = Prior Authorization; QL = Quantity Limit; LA = Limited Availability; SP = Specialty Pharmacy.ST is one of several utilization management tools noted on line items and may be enforced alongside PA/QL/LA/SP flags.
    ObservationSource implication
    Document extract primarily lists PA, QL, LA, SP flags for products; explicit step-by-step ST rules are not provided in this excerpt.Where ST is intended, the specific required prior agents or sequences are not shown here and would be defined in plan operational rules or a separate clinical policy.
    Providers should not assume a formulary line marked PA/QL implies ST unless the entry explicitly shows ST.Use product line annotations (ST) to identify step therapy; otherwise follow PA/QL processes shown for each drug.
    Palforzia stage / dosing levelRequirements/Limits (implication for coverage/step)
    PALFORZIA INITIAL DOSE ES (starter pack: 0.5, 1, 1.5, 3, 6 mg formulations)Requirements/Limits = LA, SP — limited availability and specialty dispensing indicated for initial dosing.
    PALFORZIA LEVEL 0 (1 mg dose) and LEVEL 1 (3 mg dose)Requirements/Limits = LA, SP — each listed level is flagged LA and SP, indicating administrative/site constraints rather than an explicit fail-first sequence.
    PALFORZIA LEVEL 2 – LEVEL 11 including LEVEL 10 (240 mg dose) and LEVEL 11 (maintenance 300 mg)Requirements/Limits = LA, SP for most levels — dosing organized by levels with limited access and specialty handling; no explicit inter-level step therapy algorithm provided in this excerpt.
    FindingPolicy consequence
    No explicit step therapy steps or sequences are defined within these chunks.Coverage decisions rely on line-item flags (PA, QL, LA, SP); when ST is required it will be shown explicitly on the line item otherwise PA/QL govern access.
    Contraceptive flagPotential impact on coverage pathway
    Multiple contraceptives (e.g., ANNOVERA, nicotine replacement analogs shown elsewhere) are annotated ACA or ACA, FF.ACA designation may affect cost sharing (no-cost preventive coverage where applicable) and may alter typical utilization management; LA may restrict dispensing sites. Step therapy is not specified for these products in this excerpt.
    GLP‑1 / related agentsImplication for step edits
    Several GLP‑1 and related agents (e.g., OZEMPIC, MOUNJARO, TRULICITY, RYBELSUS) are listed with PA and QL requirements.PA-driven controls are used for access; the document does not define an explicit ST hierarchy among GLP‑1 agents — step edits, if any, are likely enforced through PA criteria rather than a visible ST sequence in this extract.
    AgentST indicated?
    KERENDIA (finerenone) tabs 10/20/40 mgRequirements/Limits = QL (30 tablets/30 days), ST indicated on the line item.
    FlagInterpretation
    ACA annotations appear on some agents (e.g., select statins and preventive products).ACA flags imply programmatic coverage (e.g., preventive/no cost-share) or placement on specific formulary pathways but do not themselves define step sequences in this excerpt.
    Summary observationActionable note
    Across the provided chunks no explicit multi‑step sequences (fail‑first algorithms) are defined for the majority of products.Where ST applies it is explicitly annotated on the line item; otherwise follow PA/QL/LA/SP requirements shown per product and use plan PA processes for access management.
    Products with LA flagCoverage implication
    Examples include GATTEX (not shown in these specific chunks) and LIVMARLI (maralixibat) where Requirements/Limits = LA, PA, SP.LA indicates limited availability — dispensing or site restrictions apply and may act as an access control analogous to step restrictions; prior authorization and specialty routing are also required.
    Examples of ST‑labeled agentsPractical requirement
    AUVELITY, FETZIMA, TRINTELLIX, FLUOXETINE DR, FANAPT are shown with 'ST' on their formulary entries (e.g., FETZIMA Requirements/Limits = QL, ST).When ST is annotated providers should ensure required first‑line therapies have been tried per plan rules before submitting authorization or claim; absence of full ST sequencing details in this extract means operational ST criteria must be confirmed with EmblemHealth or the PA process.
    Gabapentin / related entriesST annotation
    Gabapentin once‑daily formulations (Gralise) and HORIZANT entries list Requirements/Limits including QL and are annotated with ST.ST applies to select gabapentin formulations per the line items; prescribers should verify prior therapy requirements before coverage is approved.
    ProductST indicated?
    IMITREX STATDOSE SYSTEM (sumatriptan solution auto‑injector 4 mg/0.5 ml)Requirements/Limits = QL (12 doses/30 days), ST — line item annotated 'ST' indicating step therapy requirement applies.

    Specified Quantity Limits (QL)

    inv-138: abacavir sulfate soln 20 mg/ml (Ziagen) — QL (960 mls/30 days)
    Abacavir sulfate oral solution (Ziagen)Quantity limit: QL 960 mls per 30 days
    Abacavir sulfate tabletsAlternate tablet limits shown: QL 60 tablets/30 days (300 mg) and QL 30 tablets/30 days for combination formulations
    Source referenceFormulary line‑items list the solution and tablet QLs explicitly
    inv-139: ISENTRESS (raltegravir) chewable — QL (180 tablets/30 days)
    ISENTRESS chewable (raltegravir)Quantity limit: QL 180 tablets per 30 days for the chewable formulation
    Other ISENTRESS presentations400 mg tablets listed with QL 60 tablets/30 days and packets with QL 360 packets/30 days in other listings
    ContextISENTRESS formulations have product‑specific QLs noted in the formulary entries
    inv-140: PAXLOVID packs — QL (11-30 tablets/30 days)
    PAXLOVID packs (nirmatrelvir/ritonavir)Quantity limits vary by pack: QL 11 tablets/30 days for the 6x150/5x100 pack; QL 20 tablets/30 days for the 10x150/10x100 pack; other pack sizes list corresponding QLs
    Pack‑specific enforcementQL is applied per pack configuration as listed in the formulary entries
    Provider implicationDispense and PA requests should reflect the pack size and corresponding QL
    inv-141: SOVALDI (sofosbuvir) — QL (28 tablets/28 days)
    SOVALDI (sofosbuvir)Quantity limit: QL 28 tablets per 28 days
    Pack vs tablet notationSOVALDI is listed with tablet and packet pack QLs (28 tablets/28 days or 28 packets/28 days) and PA/ SP where indicated
    Coverage notePA and QL are shown together for hepatitis C direct‑acting antivirals to govern coverage/course length
    inv-142: SUNLENCA therapy packs — QL (4-5 tablets/365 days)
    SUNLENCA therapy packsQuantity limit: QL 4–5 tablets per 365 days for lenacapavir therapy packs (4x300 mg or 5x300 mg packs)
    Tablet presentationSingle‑tablet listing for SUNLENCA 300 mg also shows QL 4 tablets/365 days in alternate line listing
    Yearly course QLSUNLENCA is managed as an annual therapy pack with QL expressed per 365‑day period
    inv-143: SUNLENCA - lenacapavir sodium tab 300 mg — QL (4 or 5)
    SUNLENCA — tablet QL variantsLenacapavir 300 mg tablet — QL listed as 4 tablets/365 days in one line and 5 tablets/365 days for therapy pack entries
    Packaging affects QLTherapy packs and single tablets may be assigned slightly different QLs based on pack size/course
    Specialty handlingSUNLENCA entries include LA and SP flags indicating limited availability and specialty distribution
    inv-144: SYMTUZA; TRIUMEQ; TYBOST; TIVICAY — QL (30-60)
    SYMTUZA / TRIUMEQ / TYBOST / TIVICAY examplesExamples of QL ranges: SYMTUZA / TRIUMEQ / TYBOST / TIVICAY appear with QLs of 30–60 tablets per 30 days depending on formulation/strength
    Formulation dependenceSome products show different QLs for standard vs pediatric/oral suspension forms (e.g., TRIUMEQ PD QL 180 tablets/30 days)
    Provider noteConfirm the exact formulation/strength when interpreting the listed QL
    inv-145: VOSEVI; XOFLUZA; nitazoxanide — QL examples
    VOSEVI / XOFLUZA / nitazoxanide examplesVOSEVI — QL 28 tablets/28 days; XOFLUZA — QL 2 tablets/120 days (therapy pack); nitazoxanide — QL 12 tablets/90 days
    Therapy‑specific QLsInfluenza/antiviral therapy packs and single‑course tablets have short course QLs (28/28, 120‑day, 90‑day windows)
    Course limitsThese QLs reflect course‑based dosing rather than monthly chronic supply limits
    inv-146: zidovudine syrup — QL (1920)
    Zidovudine syrupQuantity limit: QL 1920 mls per 30 days for zidovudine oral solution (10 mg/ml)
    Alternate zidovudine formsZidovudine tablets/capsules have separate QLs (e.g., 60 tablets/30 days or 180 capsules/30 days depending on formulation)
    High‑volume liquid QLsLarge mls QLs are used for liquid pediatric/adult solution presentations and must be observed when dispensing
    inv-147: abiraterone acetate — QL examples (120 tablets/30 days etc.)
    Abiraterone acetate — QL by strengthAbiraterone acetate (Zytiga) — QL 120 tablets/30 days for 250 mg and QL 60 tablets/30 days for 500 mg
    Strength‑specific limitsDifferent strengths of the same active ingredient are assigned different QLs based on expected dosing
    Provider actionUse the line‑item strength to determine the applicable QL when submitting claims or PA
    inv-148: ALECENSA — QL (240 capsules/30 days)
    ALECENSA (alectinib)Quantity limit: QL 240 capsules per 30 days
    Associated flagsALECENSA is listed with LA, PA, and SP indicating limited availability and specialty management
    Provider implicationPA and specialty routing required where annotated; ensure QL adherence on claims
    inv-149: BRAFTOVI — QL (180 capsules/30 days)
    BRAFTOVI (encorafenib)Quantity limit: QL 180 capsules per 30 days
    ContextBRAFTOVI is flagged LA/PA/QL and managed through specialty pharmacy
    Operational notePrescribers should include PA and adhere to the QL when requesting coverage
    inv-150: COMETRIQ — QL (1 carton/28 days)
    COMETRIQ therapy kit/cartonQuantity limit: QL 1 carton per 28 days for COMETRIQ therapy kits (cabozantinib s‑malate kit examples)
    Kit‑based QLsTherapy packs/kits may be limited by cartons/kit counts per 28‑day window rather than tablet counts
    Specialty handlingCOMETRIQ entries include LA, PA and SP — follow specialty authorization procedures
    inv-151: multiple listed products — assorted QL examples
    Assorted product QL examplesDocument lists many per‑product QLs such as 28 tablets/28 days; 120 tablets/30 days; 84 tablets/28 days — apply the specific line‑item QL shown
    Therapy packs and tabsSome entries present both packet and tablet forms with distinct QLs (e.g., TRIKAFTA packets vs tablets)
    Interpretation tipAlways reference the exact formulary line (strength/pack) to determine the correct QL and time window
    inv-152: VIZIMPRO (dacomitinib) tab — QL 30
    VIZIMPRO (dacomitinib)Quantity limit: QL 30 tablets per 30 days
    Prescribing noteVIZIMPRO annotated with PA and SP in oncology listings — adhere to QL when submitting PA/claims
    Unit/timeframeQL expressed as tablets per 30 days for this oral oncology agent
    inv-153: VONJO (pacritinib) cap 100 mg — QL 120
    VONJO (pacritinib) cap 100 mgQuantity limit: QL 120 capsules per 30 days
    Indication contextListed with LA/PA/SP flags in oncology section — specialty handling expected
    Claims/PA noteEnsure PA and QL are met for dispensing to avoid denial
    inv-154: VORANIGO (vorasidenib) tab 10 mg — QL 60
    VORANIGO (vorasidenib) tab 10 mgQuantity limit: QL 60 tablets per 30 days for the 10 mg strength
    Alternate strengthsHigher tablet strengths may have different QLs (document shows 40 mg listing with QL 30 tablets/30 days)
    Provider actionUse the exact strength/line item for QL determination on PA and claims
    inv-155: XOSPATA (gilteritinib) tab 40 mg — QL 90
    XOSPATA (gilteritinib) 40 mgQuantity limit: QL 90 tablets per 30 days
    Oncology managementXOSPATA entries include PA and SP flags indicating specialty pharmacy routing and authorization requirements
    Claims implicationSubmit PA and ensure QL adherence for coverage
    inv-156: XTANDI (enzalutamide) — QL 120
    XTANDI (enzalutamide)Quantity limit: QL 120 capsules/tablets per 30 days for standard presentations
    Specialty flagsXTANDI is listed with LA, PA and SP in many entries — follow specialty authorization and QL limits
    Alternate strengths/timeframesSome tablet strengths show alternate QLs (e.g., 80 mg listing QL 60 tablets/30 days)
    inv-157: testosterone cypionate im inj — QL 1
    Testosterone cypionate IM injectionQuantity limit: QL 1 vial (injection) per 28 days (PA required)
    Testosterone TD gelTestosterone transdermal gel 25 mg/2.5 gm — QL 60 packets/30 days (PA annotated)
    Pump/pen examplesVarious testosterone presentations list different QLs (vials, packets, pumps) — confirm line‑item QL
    inv-158: testosterone td gel 25 mg/2.5 gm — QL 60
    Testosterone topical gel 25 mg/2.5 gmQuantity limit: QL 60 packets per 30 days
    Alternate TD formulationsOther gel strengths and pump presentations have separate QLs (e.g., Divigel 30 packets/30 days)
    PA notationTestosterone transdermal products are frequently annotated with PA in the formulary
    inv-159: estradiol gel (Estrogel) pump — QL 1
    Estradiol gel (Estrogel) pumpQuantity limit: QL 1 pump per 30 days for the metered‑dose Estrogel pump
    Other estradiol presentationsEstradiol patches and gels show QLs in packets/grams or patches per period (e.g., 8 patches/28 days)
    Formulation noteLiquid/gel presentations list mls/grams or pump counts as the QL unit
    inv-160: ORIAHNN pack — QL 1
    ORIAHNN pack (elagolix‑estradiol‑norethindrone)Quantity limit: QL 1 pack/box per 28 days (PA and QL annotated)
    Contraceptive/combination QLsContraceptive combination packs often use a 28‑day QL window with QL 1 pack/28 days where annotated ACA or PA applies
    Provider actionFollow PA/ACA annotations and QL when prescribing ORIAHNN or similar combination packs
    inv-161: XPOVIO therapy packs — QL varies
    XPOVIO therapy packs (selinexor)Quantity limits vary by pack: examples include QL 16 tablets/28 days for some packs or QL 1 box/28 days depending on the therapy pack configuration
    Pack‑specific QLsDifferent XPOVIO pack strengths/frequencies carry different QLs (document lists multiple pack QLs)
    Specialty/PA noteXPOVIO listings include PA and SP flags — follow specialty authorization and QL on PA/claims
    inv-162: Diabetes/GLP agents — assorted QL examples
    GLP‑1/DPP‑4 and antidiabetic examplesProduct QLs vary by agent: examples include QL 30 tablets/30 days for oral agents; pen limits such as 4 pens/28 days or 4 pens/180 days for injectables; MOUNJARO/Q L 4 pens/28 days or 4 pens/180 days depending on strength
    Insulin pen/vial examplesInsulin QLs: 33 cartridges/30 days, 33 pens/30 days, 10 vials/30 days, 100 mls/30 days depending on presentation
    Provider guidanceConfirm the specific agent and presentation to apply the correct QL on PA and claims
    inv-163: Insulin products — QL examples (vials/pens/ml limits)
    Insulin product QLsExamples: HUMALOG — QL 33 cartridges/30 days or QL 100 mls/30 days; NOVOLOG — QL 10 vials/30 days or QL 33 pens/30 days; FIASP — QL 10 vials/30 days or QL 33 pens/30 days
    Presentation‑specific limitsVials, pens, and cartridges have distinct QLs — ensure PA/claims use the correct unit and timeframe
    Specialty handlingSome insulin presentations may require specialty pharmacy routing or QL enforcement
    inv-164: GALAFOLD — QL 14 capsules/28 days
    GALAFOLD (migalastat)Quantity limit: QL 14 capsules per 28 days (LA, PA, SP annotations apply)
    Specialty flagsGALAFOLD listed with LA, PA and SP — specialty handling and authorization required
    Dispensing implicationEnsure PA and specialty routing when requesting coverage and dispensing per QL
    inv-165: FOLLISTIM AQ cartridges — QL varies by strength
    FOLLISTIM AQ cartridges — variable QLsQuantity limits vary by cartridge strength: examples include QL 15 cartridges/30 days, QL 8 cartridges/30 days, or QL 5 cartridges/30 days depending on strength
    Specialty/PA flagsFOLLISTIM AQ entries include PA and SP annotations — follow specialty PA process
    Strength‑dependent QLSelect the QL corresponding to the cartridge strength when submitting PA or claims
    inv-166: JYNARQUE therapy pack — QL 56 tablets/28 days
    JYNARQUE therapy packQuantity limit: QL 56 tablets per 28 days for JYNARQUE therapy pack (LA, PA, QL, SP annotations)
    JYNARQUE 15 mg tabletQuantity limit: QL 60 tablets per 30 days for the 15 mg tablet formulation
    Specialty handlingJYNARQUE lines include LA/PA/SP designations — follow specialty authorization requirements
    inv-167: JYNARQUE 15 mg — QL 60 tablets/30 days
    JYNARQUE 15 mgQuantity limit: QL 60 tablets per 30 days for JYNARQUE 15 mg tablets
    Formulation noteDifferent JYNARQUE presentations use 28‑day or 30‑day QL windows depending on pack vs single tablet
    Provider instructionUse the exact line item when applying QL and requesting PA
    inv-168: teriparatide (Forteo) — QL 1 pen/28 days
    Teriparatide (Forteo)Quantity limit: QL 1 pen per 28 days (PA and SP annotations present)
    Administration/device QLPen‑injection biologic/treatment pens are commonly limited to one pen per 28‑day supply
    Specialty routingForteo listed with PA/SP for specialty handling where annotated
    inv-169: TRYNGOLZA — QL 1 injection device/28 days
    TRYNGOLZA injection deviceQuantity limit: QL 1 injection device per 28 days (LA, PA, SP annotations)
    Device‑based QLsSome novel injectables are limited by device/unit per period rather than milliliters or tablets
    Provider implicationFollow PA and specialty routing for device‑based therapies
    inv-170: VOXZOGO — QL 30 vials/30 days
    VOXZOGO (vosoritide)Quantity limit: QL 30 vials per 30 days
    Vial‑based limitsVial counts per 30 days are used for many infusible or injectable therapies listed (e.g., VOXZOGO) and must be followed on claims/PA
    Specialty/PA flagsVOXZOGO includes LA, PA and SP annotations — specialty authorization required
    inv-171: YORVIPATH — QL 2 pens/28 days
    YORVIPATH pensQuantity limit: QL 2 pens per 28 days
    Pen/device QLsSome self‑administered biologic therapies list QLs in pens or syringes per 28 days (e.g., YORVIPATH)
    Specialty notePA and SP annotations commonly accompany pen QLs — use specialty routing
    inv-172: enalapril solution, evolocumab, TYVASO, UPTRAVI — assorted QL examples
    Oral solution / kit QL examplesExamples include QL 1200 mls/30 days for lisinopril/ l isinopril oral solution (QBRELIS) and QL 6 syringes/28 days for evolocumab presentations
    TYVASO kits / cartridgesTYVASO starter kit QL 1 kit/180 days and maintenance kit QL 1 kit/28 days (LA, PA, SP annotations)
    UPTRAVI (selexipag)Quantity limit: QL 60 tablets per 30 days (LA, PA, SP) — follow pack/titration QLs as listed
    inv-173: TREPOSTINIL (TYVASO) — QL 1 kit/28 days or 1 kit/180 days (starter)
    TREPOSTINIL (TYVASO) kitsQuantity limit: QL 1 kit per 28 days for maintenance or QL 1 kit per 180 days for starter kit (LA, PA, QL, SP annotations)
    Site‑of‑care impactStarter kits and maintenance kits have different QLs/time windows; ensure correct kit type is referenced in PA/claims
    Specialty routingTREPOSTINIL entries include SP — specialty pharmacy or authorized infusion channels may be required
    inv-174: UPTRAVI — QL 60 tablets/30 days
    UPTRAVI (selexipag)Quantity limit: QL 60 tablets per 30 days (LA, PA, QL, SP) — titration pack QL and package QLs also noted
    Titration pack notesUPTRAVI titration packs have separate QLs (e.g., 1 package/180 days for titration) — use the specific line item
    Provider actionSubmit PA and adhere to QL and LA/SP routing to secure coverage
    inv-175: YUTREPIA — QL 112 capsules/28 days
    YUTREPIA inhalation capsulesQuantity limit: QL 112 capsules per 28 days (LA, PA, QL, SP)
    High capsule count QLsInhalation capsule products for pulmonary vasodilators often have large capsule QLs per 28 days
    Specialty handlingYUTREPIA entries include LA/PA/SP — follow specialty authorization and QL requirements
    inv-176: FASENRA PEN — QL 1 pen/28 days
    FASENRA PENQuantity limit: QL 1 pen per 28 days (LA/PA/QL/SP annotations may apply)
    NUCALA presentationsNUCALA QL varies by presentation: 1–3 syringes/pens per 28 days depending on strength/formulation
    Biologic pen QLsBiologic pens/syringes commonly have QLs of 1 per 28 days or multiple units per 28 days depending on dosing
    inv-177: NUCALA — QL 1-3 syringes/pens per 28 days depending on presentation
    NUCALA (mepolizumab) presentationsQuantity limits vary: QL 1 syringe/pen/28 days for some presentations and QL 3 syringes/28 days for others (LA, PA, SP annotations)
    Specialty routingNUCALA entries include LA/PA/QL/SP — ensure specialty pharmacy routing and PA documentation as required
    Dosing dependencyQL depends on product presentation and labeled dosing schedule
    inv-178: CF modulators — assorted QL (56-120 tablets/28-30 days)
    CF modulators QL rangeCF modulators (KALYDECO, ORKAMBI, SYMDEKO, TRIKAFTA) — QLs vary by product: examples include 56–120 tablets/28–30 days depending on formulation
    Packet vs tablet formsTRIKAFTA packets: QL 56 packets/28 days; TRIKAFTA tablet forms: QL 90 tablets/30 days
    Specialty/LA flagsCF modulators include LA/PA/QL/SP flags — specialty authorization commonly required
    inv-179: PIRFENIDONE — assorted QL depending on formulation
    PIRFENIDONE QL examplesPirfenidone: examples by formulation include QL 21 tablets/180 days; QL 180 capsules/30 days; QL 90 tablets/30 days depending on formulation
    Esbriet (pirfenidone 801 mg)QL 90 tablets per 30 days for the 801 mg tablet formulation
    Formulation dependenceDifferent capsule/tablet presentations carry different QLs — use the specific line for PA/claims
    inv-180: pirfenidone 801 mg (Esbriet) — QL 90 tablets/30 days
    Pirfenidone 801 mg (Esbriet)Quantity limit: QL 90 tablets per 30 days
    ContextEsbriet entries are annotated with PA/QL/SP in the pulmonary/fibrosis section
    Claims noteApply the 90 tablets/30 days QL for the 801 mg Esbriet tablet presentation
    inv-181: TRIKAFTA (packet forms) — QL 56 packets/28 days
    TRIKAFTA packet formsQuantity limit: QL 56 packets per 28 days for TRIKAFTA packet presentations (LA, PA, QL, SP)
    TRIKAFTA tablet formsQuantity limit: QL 90 tablets per 30 days for TRIKAFTA tablet formulations
    Specialty flagsTRIKAFTA entries include LA/PA/QL/SP — specialty authorization and QL adherence required
    inv-182: TRIKAFTA (tablet forms) — QL 90 tablets/30 days
    TRIKAFTA tablet formsQuantity limit: QL 90 tablets per 30 days for TRIKAFTA tablet presentations
    Dose/formulation noteTablet forms have a distinct QL vs packet forms; reference the exact line item for claims/PA
    Specialty handlingTRIKAFTA is annotated LA/PA/QL/SP — follow specialty pharmacy and PA procedures
    inv-183: esomeprazole suspension packets (Nexium) — QL 60 packets/30 days
    Esomeprazole suspension packets (Nexium)Quantity limit: QL 60 packets per 30 days for esomeprazole delayed‑release suspension packets
    Packet presentation QLsOral suspension/packet forms for pediatric/feeding tube use often use packet QLs per 30 days
    Claims implicationEnsure packet QL is used on claims/PA rather than tablet QLs for suspension forms
    inv-184: CIMZIA prefilled syringe — QL 4 syringes/28 days
    CIMZIA prefilled syringeQuantity limit: QL 4 syringes per 28 days (PA and SP annotations) — starter kit QL 1 kit per 180 days
    Prefilled syringe vs starter kitCIMZIA listings show both a maintenance syringe QL (4 syringes/28 days) and a starter kit QL (1 kit/180 days)
    Specialty/PA noteFollow PA and specialty routing for certolizumab products as annotated
    inv-185: CIMZIA STARTER KIT — QL 1 kit/180 days
    CIMZIA STARTER KITQuantity limit: QL 1 starter kit per 180 days
    Starter kit vs maintenanceStarter kits often have a longer QL window (e.g., 180 days) compared with maintenance syringe QLs
    Provider actionUse the kit‑specific QL when submitting PA for initiation therapy
    inv-186: ELMIRON — QL 90 capsules
    ELMIRON (pentosan polysulfate sodium)Quantity limit: QL 90 capsules per 30 days (PA indicated)
    Chronic oral therapy QLsLong‑term oral therapies may use 30‑day capsule QLs such as 90 capsules/30 days for ELMIRON
    Claims/PA noteEnsure QL is applied on PA/claims for ELMIRON to avoid processing issues
    inv-187: Endometrin — QL 84 suppositories
    Endometrin (progesterone vaginal insert)Quantity limit: QL 84 suppositories per 28 days
    Vaginal insert QLsSome vaginal/progesterone delivery systems use large QLs (e.g., 84 suppositories/28 days) reflecting frequent dosing regimens
    Formulary noteObserve the specific QL unit (suppositories) and period when claiming or authorizing Endometrin
    inv-188: duloxetine pellets 20 mg — QL 180 capsules
    Duloxetine pellets 20 mgQuantity limit: QL 180 capsules per 30 days for duloxetine enteric‑coated pellets 20 mg
    High capsule countsCertain SSRI/SNRI pellet formulations list high QLs (e.g., 180 capsules/30 days) for multi‑dose packaging
    Claims implicationUse the pellet/tablet QL shown on line items when processing claims or PA
    inv-189: ZURZUVAE — QL 28 or 14 capsules
    ZURZUVAE (zuranolone)Quantity limit: QL 28 or 14 capsules per specified course/window (document shows both 28 and 14 capsule options depending on product form)
    Course‑based QLsSome CNS/novel agents use course‑based QLs expressed as capsules per treatment period (e.g., 14 or 28 capsules)
    Specialty flagsZURZUVAE is listed with SP annotation — specialty routing and QL enforcement apply
    inv-190: cladribine (Mavenclad) — QL 8-20 tablets
    MAVENCLAD (cladribine) therapy packsQuantity limits: QL ranges shown per therapy pack — examples include QL 8–20 tablets per defined course (multiple pack sizes listed)
    Course‑based dosing windowsMavenclad therapy packs are managed with multi‑month QL windows (e.g., 301 days referenced for course totals)
    PA/SP/LA flagsMavenclad entries include LA, PA, QL and SP annotations — specialty authorization required
    inv-191: fingolimod (Gilenya) — QL 30 tablets/30 days
    Fingolimod (Gilenya)Quantity limit: QL 30 tablets per 30 days (PA/QL/SP annotations)
    Alternate Gilenya listingsSome fingolimod strengths/presentations include PA and SP flags and may show different QLs in starter or pack forms
    Provider instructionFollow the Gilenya line item QL and specialty authorization when submitting PA/claims
    inv-192: sodium oxybate (Xyrem) — QL 540 mls/30 days
    Sodium oxybate (Xyrem / XYWAV)Quantity limit: QL 540 mls per 30 days (oral solution 500 mg/ml entries show QL 540 mls/30 days)
    High‑volume liquid QLsSodium oxybate and similar liquids use mls per 30 days as the QL unit; ensure claims/PA use the mls unit
    Flags and restrictionsXyrem entries include FF, LA, PA, QL and SP annotations — multiple utilization controls apply
    inv-193: WAINUA — QL 1 pen/30 days; VYLEESI — QL 6 pens/30 days
    WAINUA (eplontersen) penQuantity limit: QL 1 pen per 30 days (LA, PA, QL, SP annotations)
    VYLEESI (bremelanotide) pensQuantity limit: QL 6 pens per 30 days (LA, PA, QL, SP annotations)
    Device QLsInjectable device‑based therapies commonly use pens/devices per 30 days as the QL unit
    inv-195: adalimumab-aaty auto-injector kit 80 mg/0.8ml — QL 1 kit
    Adalimumab‑aaty auto‑injector kitQuantity limit: QL 1 kit (often per 180 days for certain kit configurations) — PA and SP annotations apply
    Kit vs pen/syringe QLsBiosimilar/biologic products may have kit QLs (1 kit/180 days) or pen/syringe QLs (e.g., 2 pens/28 days) depending on presentation
    Provider actionUse the specific kit/pen/syringe QL shown when submitting PA or claims
    inv-196: ENBREL prefilled syringes — QL 4 syringes
    ENBREL prefilled syringesQuantity limit: QL 4 syringes per 28 days (PA and SP annotations) — other cartridge/prefill presentations list similar QLs
    Prefill/cartridge variantsENBREL entries include QLs for syringes, cartridges and pens (e.g., 4 cartridges/28 days or 8 vials/28 days) depending on presentation
    Specialty handlingFollow PA and specialty routing for ENBREL family products to ensure coverage
    inv-197: XELJANZ tab 5 mg — QL 60 tablets
    XELJANZ (tofacitinib) 5 mg tabletsQuantity limit: QL 60 tablets per 30 days for XELJANZ 5 mg
    Oral immunomodulator QLsOral immunomodulators and JAK inhibitors often have 30‑day tablet QLs (e.g., 60 tablets/30 days) on the formulary
    PA/SP annotationsSome listings include PA or SP alongside QL depending on the agent and indication
    inv-198: AJOVY 225 mg — QL 3 injection devices
    AJOVY 225 mg (fremanezumab)Quantity limit: QL 3 injection devices per 84 days (PA annotated)
    Quarterly device limitsSome migraine biologics list device QLs over multi‑month windows (e.g., 3 devices/84 days) rather than monthly counts
    PA/claims implicationSubmit PA and use the stated multi‑month QL window when processing claims
    inv-199: IMITREX STATDOSE SYSTEM — QL 12 doses
    IMITREX STATDOSE systemQuantity limit: QL 12 doses per 30 days (presentation‑specific QL shown)
    Dose‑based QLsSystems delivering multiple acute doses (e.g., STATDOSE) use dose counts per 30 days as the QL unit
    Step therapy noteSome acute systems are annotated ST in addition to QL — check for step requirements

    Specialty Pharmacy & Administration Sites

    Billing Rule

    Confirm infusion center or specialty pharmacy routing for LA/SP drugs

    Products flagged as SP or requiring PA may also be limited to specialty pharmacy or infusion/clinic settings; confirm site‑of‑care or specialty pharmacy routing and include that information in PA requests.

    • Certain agents flagged LA or SP indicate administration/dispensing under specific programs or sites (infusion center or specialty pharmacy).
    • Many specialty products require SP handling and may be restricted to infusion centers when LA is present.
    Billing Rule

    Dispense SP‑designated products via specialty pharmacy

    If a product is designated SP, route dispensing through the plan's specialty pharmacy channel; many listed specialty products are managed under SP programs.

    • Products marked SP must be dispensed through specialty pharmacy channels per the formulary.
    • Specialty oncology oral agents and biologics are commonly managed via SP.
    Billing Rule

    Oncology oral agents: manage via specialty pharmacy and PA

    Many specialty oncology oral agents are managed under specialty pharmacy programs; ensure PA approval and specialty pharmacy dispensing for SP‑annotated oncology agents.

    • Oncology oral agents in chunks 61–92 frequently carry PA, QL, LA, and SP flags.
    • Specialty pharmacy distribution is indicated for numerous oral oncology products.
    Billing Rule

    Ensure specialty pharmacy handling for SP agents

    Most specialty agents require specialty pharmacy handling and PA; confirm specialty pharmacy enrollment and route orders accordingly for SP medications.

    • Many specialty agents (e.g., GENOTROPIN, IMCIVREE) require PA and SP handling.
    • Specialty pharmacy routing is required for agents marked SP.
    Billing Rule

    Manage SP products via specialty channels; some LA products restricted to infusion sites

    Specialty‑designated products are dispensed through specialty channels and some infusible/IV products are restricted to infusion sites; confirm the appropriate dispensing site when SP or LA is shown.

    • Products marked SP are managed as specialty pharmacy; some flagged LA may be restricted to infusion or limited sites.
    • TYVASO, TREPOSTINIL and similar products list LA/PA/QL and SP handling.
    Billing Rule

    Verify PA and SP routing for specialty‑designated products

    Numerous products across the formulary are designated as specialty (SP); verify PA and specialty pharmacy routing for these items before prescribing or dispensing.

    • Many specialty‑designated products are listed with PA/QL/SP flags.
    • Examples include biologics and complex specialty therapies in chunks 180–190.
    Billing Rule

    Follow site‑of‑care restrictions for LA/SP products

    When a product is marked LA or SP, follow site‑of‑care routing implications — some must be administered in infusion centers or dispensed only via specialty pharmacy programs.

    • Products marked 'SP' are managed as specialty pharmacy; some products also flagged 'LA' indicate limited access or specific site requirements.
    • Check the line item for infusion center or specialty pharmacy restrictions.
    Vancomycin HCl capsules and oral solution (Vancocin, Firvanq) are listed (Drug Tier = 1).
    XIFAXAN (rifaximin)Rifaximin tablets 200 mg and 550 mg are listed (Drug Tier = 2).
    CAYSTON (aztreonam lysine) inhalationAztreonam lysine for inhalation solution 75 mg listed with Requirements/Limits = LA, SP.
    Vaccines and ACA flagVaccines including ABRYSVO, AREXVY, COMIRNATY 2025–26, GARDASIL 9, SHINGRIX, SPIKEVAX and others are listed; many vaccine entries are flagged ACA (Affordable Care Act) for preventive coverage.
    Mavenclad repeated listingMavenclad (cladribine) therapy packs are listed multiple times with LA, PA, QL (e.g., 8–14 tablets per 301-day course) and SP handling.
    Mayzent (siponimod) strengthsMayzent (siponimod fumarate) tablets listed in 0.25 mg, 1 mg, and 2 mg strengths with LA/PA/QL/SP annotations.
    Memantine presentationsMemantine HCl oral solution 2 mg/ml and tablets 5 mg and 10 mg are listed with PA and QL annotations in the formulary.
    Nicotine cessation productsNicotine polacrilex gum and lozenges (2 mg, 4 mg), patches and starter packs are listed and annotated ACA (smoking cessation benefit).
    Tetrabenazine (Xenazine) strengthsTetrabenazine tablets 12.5 mg and 25 mg are listed with Requirements/Limits including PA and QL (e.g., 120–240 tablets/30 days depending on strength).
    Opioid analgesics (coverage flags)Various opioid analgesics (fentanyl patches, morphine sulfate, hydrocodone combination products) are listed with multiple QL and PA flags — ensure PA/QL compliance when prescribing.
    Rifaximin (XIFAXAN)Rifaximin tablets 200 mg and 550 mg are explicitly listed (Drug Tier = 2)
    CAYSTON inhaled aztreonamAztreonam lysine for inhalation solution 75 mg listed; Requirements/Limits = LA, SP
    Vaccines (examples)ABRYSVO, AREXVY, COMIRNATY 2025–26, GARDASIL 9, SHINGRIX, SPIKEVAX and others listed (many flagged ACA)
    Mavenclad (cladribine) therapy packsMAVENCLAD therapy packs listed repeatedly with LA, PA, QL (e.g., 8–20 tablets across course), SP
    Mayzent strengthsMayzent (siponimod fumarate) tablets 0.25 mg, 1 mg, 2 mg listed with LA, PA, QL, SP
    Memantine formulationsMemantine HCl oral solution 2 mg/ml and tablets 5 mg/10 mg listed; PA and QL references noted
    Nicotine cessation productsNicotine gum, lozenge, patch and starter kits listed and annotated ACA for smoking cessation coverage
    Tetrabenazine (Xenazine) tablets12.5 mg and 25 mg tablets listed with PA, QL and SP annotations
    Opioid analgesics — examplesFentanyl patches, morphine sulfate and hydrocodone combination products listed with QL/PA controls — obtain required PA and adhere to QL
    XIFAXAN strengthsRifaximin (XIFAXAN) tablets 200 mg and 550 mg listed (Drug Tier = 2)
    CAYSTON inhalation solutionAztreonam lysine for inhalation solution 75 mg listed with LA and SP annotations.
    Vaccine examples and ACA flagMultiple vaccines (ABRYSVO, AREXVY, COMIRNATY 2025-26, GARDASIL 9, SHINGRIX, SPIKEVAX, etc.) are listed; many are annotated ACA for preventive coverage.
    Mavenclad (cladribine) therapy packs repeatedMavenclad therapy packs listed with LA, PA, QL (examples: 8–14 tablets/301 days) and specialty routing (SP)
    Mayzent (siponimod) dosingMayzent tablets 0.25 mg, 1 mg, 2 mg listed with LA/PA/QL/SP flags.
    Memantine presentations recordedMemantine HCl oral solution 2 mg/ml and tablet strengths 5 mg, 10 mg are present with PA/QL notes.
    Nicotine cessation (ACA)Nicotine polacrilex gum/lozenge/patch and kits listed with ACA coverage annotation.
    Tetrabenazine (Xenazine) strengths and limitsTetrabenazine tablets 12.5 mg and 25 mg listed; Requirements/Limits include PA and QL (e.g., 120–240 tablets/30 days depending on strength)
    Opioid analgesics and utilization controlsVarious opioid analgesics (fentanyl patch, morphine sulfate, hydrocodone combos) are listed with QL and PA flags — ensure required PA and respect QL to avoid denial.
    Vancomycin HCl capsules and oral solution (Vancocin, Firvanq) are listed (Drug Tier = 1)
    Rifaximin (XIFAXAN) 200 mg & 550 mgRifaximin tablets 200 mg and 550 mg recorded on formulary (Drug Tier = 2)
    CAYSTON inhalation 75 mgCAYSTON — aztreonam lysine for inhalation solution 75 mg listed with LA and SP requirements.
    Vaccines (selected, many ACA)Vaccines such as ABRYSVO, AREXVY, COMIRNATY 2025–26, GARDASIL 9, SHINGRIX, SPIKEVAX appear in the vaccine cluster; many vaccine entries show ACA designation.
    Mavenclad (cladribine) repeated entriesMavenclad therapy packs are listed multiple times with LA, PA, QL (e.g., 8–20 tablets per course) and specialty handling (SP)
    Mayzent — siponimod fumarate strengthsMayzent tablets 0.25 mg, 1 mg, and 2 mg are listed and flagged LA/PA/QL/SP.
    Memantine solution & tabletsMemantine HCl oral solution 2 mg/ml and tablets 5 mg/10 mg listed; Requirements/Limits include PA and QL examples.
    Nicotine cessation products (ACA)Nicotine gum, lozenge, patch and starter kits listed with ACA preventive coverage annotation.
    Tetrabenazine (Xenazine) 12.5/25 mgTetrabenazine tablets 12.5 mg and 25 mg listed with PA and QL annotations (SP routing indicated).
    Opioid analgesics (fentanyl, morphine, hydrocodone)Various opioid analgesics including fentanyl patches, morphine sulfate, and hydrocodone combination products are listed with multiple QL and PA flags — obtain PA and follow QL restrictions to prevent denial.